{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:45:20Z","timestamp":1790232320505,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.phrs.2021.105579","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T19:17:08Z","timestamp":1616786228000},"page":"105579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies"],"prefix":"10.1016","volume":"168","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105579_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105579_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105579_bib3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1194\/jlr.S092130","article-title":"Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance","volume":"60","author":"Paddock","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2021.105579_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2004.04.150","article-title":"The ErbB\/HER receptor protein-tyrosine kinases and cancer","volume":"319","author":"Roskoski","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105579_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","article-title":"Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor","volume":"337","author":"Roskoski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105579_bib11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","article-title":"Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor","volume":"338","author":"Roskoski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105579_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit. Rev. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2021.105579_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbrc.2008.07.121","article-title":"VEGF receptor protein-tyrosine kinases: structure and regulation","volume":"375","author":"Roskoski","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105579_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1126\/science.275.5300.665","article-title":"Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate","volume":"275","author":"Franke","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105579_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/biom9090402","article-title":"For better or worse: the potential for dose limiting the on-target toxicity of PI 3-kinase inhibitors","volume":"9","author":"Buchanan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2021.105579_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105579_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2020.08.022","article-title":"Can next-generation PI3K inhibitors unlock the full potential of the class in patients with B-cell lymphoma?","volume":"21","author":"Phillips","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.phrs.2021.105579_bib22","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1038\/ncomms8400","article-title":"PI3K-C2\u03b3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling","volume":"6","author":"Braccini","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105579_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/332644a0","article-title":"Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate","volume":"332","author":"Whitman","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105579_bib24","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1074\/jbc.R117.000629","article-title":"Phosphoinositide conversion in endocytosis and the endolysosomal system","volume":"293","author":"Wallroth","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib25","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.2147\/OTT.S268899","article-title":"Lights and shade of next-generation PI3K inhibitors in chronic lymphocytic leukemia","volume":"13","author":"Visentin","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.phrs.2021.105579_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0092-8674(93)90404-E","article-title":"SH2 domains recognize specific phosphopeptide sequences","volume":"72","author":"Zhou","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105579_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1242\/jcs.1994.Supplement_18.18","article-title":"Specificity in recognition of phosphopeptides by src-homology 2 domains","volume":"18","author":"Cantley","year":"1994","journal-title":"J. Cell Sci. Suppl."},{"key":"10.1016\/j.phrs.2021.105579_bib28","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-kinase, growth disorders, and cancer","volume":"379","author":"Goncalves","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105579_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.phrs.2021.105579_bib30","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2021.105579_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2021.105579_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105579_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105579_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2021.105579_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetinib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105579_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105579_bib42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging Ras back in the ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2021.105579_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105579_bib44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105579_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105579_bib46","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A pan-cancer proteogenomic atlas of PI3K\/AKT\/mTOR pathway alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2021.105579_bib47","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/bcr3601","article-title":"Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells","volume":"16","author":"Rexer","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.phrs.2021.105579_bib48","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105579_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"195","key":"10.1016\/j.phrs.2021.105579_bib50","doi-asserted-by":"crossref","first-page":"re2","DOI":"10.1126\/scisignal.2002165","article-title":"Structural basis for activation and inhibition of class I phosphoinositide 3-kinases","volume":"4","author":"Vadas","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2021.105579_bib51","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1016\/j.jmb.2020.09.002","article-title":"Structural features that distinguish inactive and active PI3K lipid kinases","volume":"432","author":"Zhang","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2021.105579_bib52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1042\/BST0370615","article-title":"Form and flexibility in phosphoinositide 3-kinases","volume":"37","author":"Williams","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.phrs.2021.105579_bib53","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105579_bib54","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2021.105579_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2021.105579_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib59","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1074\/jbc.M116.772426","article-title":"Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase \u03b1 that are critical for catalysis and substrate recognition","volume":"292","author":"Maheshwari","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib60","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.phrs.2021.105579_bib61","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/molecules23071791","article-title":"Synthesis and PI3 kinase inhibition activity of a wortmannin-leucine derivative","volume":"23","author":"Cantrell","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2021.105579_bib62","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/jacs.7b08979","article-title":"Selectively targeting the kinome-conserved lysine of PI3K\u03b4 as a general approach to covalent kinase inhibition","volume":"140","author":"Dalton","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2021.105579_bib63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib65","doi-asserted-by":"crossref","first-page":"D562","DOI":"10.1093\/nar\/gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","volume":"49","author":"Kanev","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2021.105579_bib66","first-page":"197","article-title":"Kinase-centric computational drug development","volume":"50","author":"Kooistra","year":"2017","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib67","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib68","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2021.105579_bib69","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2021.105579_bib70","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2021.105579_bib71","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2021.105579_bib72","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(19840201)53:3+<630::AID-CNCR2820531308>3.0.CO;2-3","article-title":"Steroid-hormone receptors in breast cancer","volume":"53","author":"Wittliff","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2021.105579_bib73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2021.105579_bib74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2021.105579_bib75","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105579_bib76","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105579_bib77","series-title":"The MD Anderson Manual of Medical Oncology","first-page":"133","article-title":"Indolent lymphomas","author":"Nastoupil","year":"2016"},{"key":"10.1016\/j.phrs.2021.105579_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib79","series-title":"The MD Anderson Manual of Medical oncology","first-page":"143","article-title":"Indolent lymphomas","author":"Nastoupil","year":"2016"},{"key":"10.1016\/j.phrs.2021.105579_bib80","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.phrs.2021.105579_bib81","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","article-title":"Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation","volume":"23","author":"Furet","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2021.105579_bib82","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105579_bib83","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2021.105579_bib84","first-page":"251","article-title":"Alpelisib in the treatment of breast cancer: a short review on the emerging clinical data","volume":"12","author":"Armaghani","year":"2020","journal-title":"Breast Cancer (Dove Med. Press)"},{"key":"10.1016\/j.phrs.2021.105579_bib85","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A pharmacological map of the PI3-K family defines a role for p110\u03b1 in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2021.105579_bib86","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cmdc.201600148","article-title":"Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946)","volume":"11","author":"Scott","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2021.105579_bib87","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/1060028019833992","article-title":"Copanlisib: an intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma","volume":"53","author":"Eltantawy","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105579_bib88","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2021.105579_bib89","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","article-title":"Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma","author":"Panayiotidis","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2021.105579_bib90","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105579_bib91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the management of lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105579_bib92","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110\u03b4 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105579_bib93","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2021.105579_bib94","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2021.105579_bib95","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLC\u03b32","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2021.105579_bib96","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2021.105579_bib97","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","article-title":"IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells","volume":"124","author":"Dong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105579_bib98","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2021.105579_bib99","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2021.105579_bib100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2016-08-731240","article-title":"Silencing c-Myc translation as a therapeutic strategy through targeting PI3K\u03b4 and CK1\u03b5 in hematological malignancies","volume":"129","author":"Deng","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.phrs.2021.105579_bib101","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11899-019-00540-w","article-title":"The role of PI3K inhibition in lymphoid malignancies","volume":"14","author":"von Keudell","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.phrs.2021.105579_bib102","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2021.105579_bib103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105579_bib104","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2021.105579_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6468(09)04801-2","article-title":"Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design","volume":"48","author":"Smith","year":"2009","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib106","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105579_bib107","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11095-015-1779-y","article-title":"Thermodynamic proxies to compensate for biases in drug discovery methods","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib108","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105579_bib109","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2021.105579_bib110","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib111","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib112","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib113","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2021.105579_bib114","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105579_bib115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2021.105579_bib116","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2021.105579_bib117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.phrs.2021.105579_bib118","first-page":"4493","article-title":"Cancer anorexia-cachexia syndrome: are neuropeptides the key?","volume":"59","author":"Inui","year":"1999","journal-title":"Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2021.105579_bib119","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.phrs.2021.105579_bib120","doi-asserted-by":"crossref","first-page":"G899","DOI":"10.1152\/ajpgi.00408.2003","article-title":"G protein-mediated dysfunction of excitation-contraction coupling in ileal inflammation","volume":"286","author":"Shi","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.phrs.2021.105579_bib121","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2021.105579_bib122","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","article-title":"Small-molecule kinase inhibitors for the treatment of nononcologic diseases","volume":"64","author":"Xie","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105579_bib123","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2021.105579_bib124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105579_bib125","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1200\/JCO.2011.40.9243","article-title":"Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2021.105579_bib126","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","article-title":"Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer","volume":"16","author":"Hopkins","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105579_bib127","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105579_bib128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:20:42Z","timestamp":1760912442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821001638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":128,"alternative-id":["S1043661821001638"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105579","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105579"}}